Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ:MRSN) will participate in a fireside chat on February 24, 2021, at 10:00 a.m. ET, during the SVB Leerink 10th Annual Global Healthcare Conference. Investors can access a live webcast on the company’s website, with an archived replay available for 90 days post-event. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, with lead candidate upifitamab rilsodotin (XMT-1536) in clinical studies for ovarian cancer and NSCLC. The company also has several promising ADCs in its pipeline targeting specific tumor types.

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company’s management team will participate in a fireside chat on Wednesday, February 24, 2021 at 10:00 a.m. ET at the SVB Leerink 10^th Annual Global Healthcare Conference.   

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90-days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (XMT-1536, UpRi), is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:
Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com

FAQ

When is Mersana Therapeutics participating in the fireside chat?

Mersana Therapeutics will participate in a fireside chat on February 24, 2021, at 10:00 a.m. ET.

Where can I watch the Mersana Therapeutics fireside chat?

You can watch the Mersana Therapeutics fireside chat live on their website in the Investors & Media section.

What is Mersana Therapeutics' lead product candidate?

Mersana Therapeutics' lead product candidate is upifitamab rilsodotin (XMT-1536), targeting ovarian cancer and NSCLC.

What is the focus of Mersana Therapeutics?

Mersana Therapeutics focuses on developing antibody-drug conjugates for cancers with high unmet medical needs.

What are Mersana Therapeutics' clinical-stage programs?

Mersana has clinical-stage programs including upifitamab rilsodotin, XMT-1592, XMT-1660, and XMT-2056.